Impact of Therapeutic Patient Education on the Toxicity of Immune Checkpoint Inhibitors in Oncology

Institut Cancerologie de l'Ouest412 enrolled

Overview

The aim of this therapeutic education program is to reduce the apparition of immune-related Adverse Event with patients treated with ICI

This study aims to highlight the impact of Patient Therapeutic Education (TPE) in oncology. TPE is an integral part of the care pathway for patients with a chronic pathology such as diabetes, asthma, chronic obstructive pulmonary disease, cardiovascular diseases requiring anticoagulants, haemophilia, renal failure, HIV infection, autoimmune diseases etc.... front of therapeutic progress, many cancers are now taken for a chronic disease. In oncology, TPE starts to grow. Indeed, TPE makes the patient more autonomous, which could reduce the occurrence and / or aggravation of some toxicities, improve the quality of life, the effectiveness of treatment and optimize health costs. Therefore, it is important to develop programme of therapeutic education in oncology. The toxicity of ICI is unusual and sometimes lethal. This toxicity must be recognized and managed quickly to maintain a satisfactory dose-intensity. TPE finds its place by raising awareness among patient to the occurrence of these toxicities. This randomized TPE versus standard care study project will assess the contribution of education in the management of severe toxicities. The investigators believe that changes in patient behaviour will reduce the number of toxicities ≥3 in the TPE arm.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

NONE

Enrollment

412

Conditions

Therapeutic Patient Education Immune Checkpoint Inhibitors Melanoma Advanced Non-small Cell Lung Cancer Renal Cell Carcinoma Head and Neck Cancer Immune-related Adverse Event

Interventions

Therapeutic education programBEHAVIORAL

Patient will have 5 educational therapy workshops. The first educational therapy workshops will be realized at cycle 1 and the last one within 25 weeks after starting treatment

Usual InformationBEHAVIORAL

Patient receive usual informations

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patient with Melanoma, Non-Small Cell Bronchial Cancer, renal cell carcinoma, Ca carcinomas of the upper airways to be treated with ICI * Patient who has never received treatment by ICI * Informed patient who signed his consent * Age \> or = 18 years * Social insurance Exclusion Criteria: * Patient receiving corticosteroid or immunosuppressant 14 days before inclusion * Immunocompromised patient * Uncontrolled brain metastases * Refusal to participate, patient protected by guardianship * Patient unable to understand the study or unable to follow the education sessions

Locations (9)

Chu Angers

Angers, France

Institut de Cancerologie de L'Ouest

Angers, France

Centre Francois Baclesse

Caen, France

Centre D'Oncologie Et de Radiotherapie 37

Chambray-lès-Tours, France

Outcomes

Primary Outcomes

Proportion of Participants With at Least One Grade ≥3 Immune-related Adverse Event (irAE) (CTCAE v5.0) Within 25 Weeks After Initiation of Immune Checkpoint Inhibitor (ICI) Treatment

The primary outcome is the occurrence of at least one immune-related adverse event (irAE) of Grade ≥3, as defined by the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0, during the 25 weeks following initiation of immune checkpoint inhibitor (ICI) treatment. This outcome is compared between the experimental group receiving Therapeutic Patient Education (TPE) and the control group receiving usual information.

Time frame: 25 weeks

Secondary Outcomes

Number of Immune Checkpoint Inhibitor (ICI) Injections Received During the Study Period

This outcome measures the total number of immune checkpoint inhibitor (ICI) injections received by each participant over the course of the study.

Time frame: 12 months

Anxiety Level Assessed by the Hospital Anxiety and Depression Scale (HADS-A)

This outcome assesses patients' anxiety level using the Hospital Anxiety and Depression Scale - Anxiety subscale (HADS-A), a validated self-report instrument designed to measure the severity of anxiety symptoms in medical populations. The HADS-A subscale consists of 7 items, each scored from 0 to 3, yielding a total score ranging from 0 to 21. Minimum score: 0 (no anxiety symptoms) Maximum score: 21 (maximum anxiety severity) Interpretation: Lower scores indicate better outcomes (lower anxiety levels). Higher scores indicate worse outcomes (greater anxiety symptoms). Scores are calculated as the sum of the 7 item scores. Results will be compared between treatment groups at the specified time point.ps.

Time frame: 12 months

Global Health Status/Quality of Life Assessed by Thethe European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Questionnaire

This outcome evaluates patients' overall quality of life using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30), a validated cancer-specific instrument assessing multiple dimensions of quality of life. The Global Health Status/Quality of Life scale of the EORTC QLQ-C30 is based on 2 items, each scored from 1 to 7. Raw scores are linearly transformed to a 0-100 scale according to the EORTC scoring manual. Minimum score (transformed): 0 Maximum score (transformed): 100 Interpretation: Higher scores indicate better outcomes (better overall quality of life and global health status). Lower scores indicate worse outcomes (poorer quality of life). The final score is calculated by averaging the item scores and applying a linear transformation to a 0-100 scale. Results will be compared between treatment groups at the specified time point.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.